OneOme, co-founded by Mayo Clinic, focuses on providing evidence-based pharmacogenomic solutions to improve patient outcomes and reduce healthcare costs through personalized medication decisions. The company offers pharmacogenomic testing services that help healthcare providers tailor drug prescriptions based on an individual’s genetic makeup, ensuring more effective and safer treatments. OneOme aims to integrate pharmacogenomics into everyday clinical practice, making personalized medicine accessible and actionable for health systems and payers.
Notable affiliations include the prestigious Mayo Clinic, which lends significant credibility and expertise to OneOme's initiatives. The company has achieved key milestones in advancing pharmacogenomic applications, contributing to the broader acceptance and implementation of personalized medicine. By enabling more precise medication management, OneOme has had a substantial impact on patient care, improving therapeutic outcomes and reducing adverse drug reactions.
